We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 2,872

Louisiana federal district court ruling turns the duty to preserve evidence on its head
  • Dentons
  • USA
  • July 30 2015

In 2014, a Louisiana federal district court jury decided that two pharmaceutical companies should pay a staggering $9 billion in punitive damages (6


Generic labels can omit orphan drug indications to avoid brand exclusivity rights
  • McDermott Will & Emery
  • USA
  • July 30 2015

Two hours after the U.S. Food and Drug Administration (FDA) approved generic versions of Abilify (aripiprazole) (excluding pediatric indications and


Suspected off-label infringing uses do not equal inducement
  • McDermott Will & Emery
  • USA
  • July 30 2015

On May 6, 2015, the U.S. Court of Appeals for the Federal Circuit issued its full opinion affirming the U.S. District Court for the District of


Little reprieve for prisoner Zyprexa suit
  • Reed Smith LLP
  • USA
  • July 22 2015

Happy birthday, Louise Fletcher, who won an Academy Award for her portrayal of the sadistic Nurse Ratched in One Flew Over the Cuckoo's Nest (1975


No prescription medical product strict liability in Pennsylvania
  • Dechert LLP
  • USA
  • July 21 2015

If you are a parent, you've probably thought (more than once) that you speak a language your children do not understand. After all, when you say "put


No duty to warn hospital under learned intermediary doctrine
  • Weil Gotshal & Manges LLP
  • USA
  • July 17 2015

Here are the Monitor we routinely cover the learned intermediary doctrine and its application in failure to warn suits. Just last week, the Court of


Rescue Remedy decision confirms that CLRA notice requirement has real teeth
  • Morrison & Foerster LLP
  • USA
  • July 15 2015

A recent decision from the Southern District of California demonstrates the potential narrowing effect of a failure to strictly comply with the


MDL shenanigans disallowed
  • Dechert LLP
  • USA
  • July 14 2015

Today’s case is a simple and straightforward message to plaintiffs you can’t use 1404 transfers to create an MDL after the Judicial Panel on


Court excludes expert’s opinion as unreliable for failure to properly consider statistical significance, but plaintiffs get Daubert do-over anyway
  • Barnes & Thornburg LLP
  • USA
  • July 14 2015

Toxic tort cases, similar to product liability actions, are often won or lost based on the strength of expert testimony. Thus, keeping plaintiffs'


Court of common pleas leaves standing Janssen’s victory in second Risperdal trial
  • Cozen O'Connor
  • USA
  • July 13 2015

The trial judge in the second Risperdal trial denied plaintiff's post-trial motion for a new trial, upholding the jury's determination that